BioSpace News Archive

Shineco, Inc. (“Shineco” or the “Company"; NASDAQ: TYHT), a producer and distributor of Chinese herbal medicines, organic agricultural produce, hemp products, and various health and well-being focused plant-based products in China, announced today that it completed its first board meeting (the “Meeting”) for fiscal year 2019 held on November 26, 2019 in Beijing, China

Variantyx announced today that it will be presenting its Genomic Unity® Epilepsy Analysis testing program at the American Epilepsy Society (AES) annual meeting December 7-9 in Baltimore, Maryland.

Canadians want access to the latest treatments for themselves, their families and their friends— especially for cancers, rare diseases and conditions with limited treatment options.

Bayer today announced the publication of an analysis of the PROTECT VIII extension study in which a subset of 33 patients with hemophilia A who received five years of prophylactic treatment with Jivi® (antihemophilic factor [recombinant] PEGylated-aucl) maintained a safety and efficacy profile that was consistent with a prior analysis of the same subset, as well as with an analysis of the pivotal Phase III PROTECT VIII main study

Harris Williams, a global investment bank specializing in M&A advisory services, announces that it advised Longs Pharmacy Solutions (Longs), a portfolio company of Tailwind Capital (Tailwind), on its sale to PharMedQuest, a portfolio company of Kinderhook Industries, LLC (Kinderhook).

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved AVSOLA™ (infliximab-axxq) for all approved indications of the reference product, Remicade® (infliximab):

Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a leading global producer of plasma-derived medicines, today concluded more than a year of encouraging results of its AMBAR (Alzheimer Management by Albumin Replacement) clinical trial with the presentation of new neuroimaging data that show the reduction in the progression of the disease in patients with mild-to-moderate Alzheimer’s disease

Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced that the Compensation Committee of Cara’s Board of Directors has approved the grant of non-qualified stock options to purchase an aggregate of 47,500 shares of common stock,

CytomX Therapeutics, Inc. announced that on November 15, 2019, the Company granted six new employees options to purchase a total of 30,000 shares of the Company’s common stock at an exercise price per share equal to $5.36, which was the closing trading price on November 15, 2019, the date of the grant.

Dr. Reddy’s Laboratories Ltd. announced the launch of Deferasirox Film-Coated Tablets, 90 mg and 360 mg, a therapeutically equivalent generic version of Jadenu® Film-Coated Tablets, 90 mg, 180 mg, and 360 mg, approved by the U.S. Food and Drug Administration.